Manages hypertension. ANDA 216399, held by Aiping Pharmaceutical. Guanfacine Hydrochloride.
As of Nov 21, 2026, ANDA 216399 (Guanfacine Hydrochloride), held by Aiping Pharmaceutical, was first approved by FDA on Jun 8, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Guanfacine tablets, USP are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 8, 2022 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters